At Lhasa, we believe that the future of science is built on collaboration and the brilliance of the next generation. We are …
Understanding the metabolic fate of compounds is a requirement for safe pharmaceutical development. Whether supporting early-stage drug discovery, conducting impurity qualification for …
Mutagenicity assessment is no longer debated; it is embedded within regulatory science. The more important question today is not whether in silico …
Approaching regulatory compliance with confidence ICH Q3D guidelines require assessing and controlling elemental impurities for regulatory compliant development of drug products. The …
We’re delighted to share that Lhasa Limited has been shortlisted for the Lush Prize 2026 in the Science category, an award recognising …
Just before the holiday period, our community voted on the most impactful scientific papers of the year authored by industry and regulatory …